MedTrace Logo

Plasmodium Immunotherapy for Advanced Ovarian Cancer

NCT05924776 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-07-22

No results posted yet for this study

Summary

The main purpose of this study is to evaluate the safety and effectiveness of Plasmodium immunotherapy in the treatment of advanced ovarian cancer. This study plans to enroll 30 patients with advanced ovarian cancer. Each patient is inoculated with Plasmodium vivax 1-5 × 10\^6, observe the time when the parasite is detected in the peripheral blood of the subjects after the inoculation of Plasmodium, the change of the parasite density in the peripheral blood of the whole treatment cycle and the control effect of the drug on the parasite density, the main clinical symptoms and signs, laboratory test indicators, immunological test indicators and changes in the quality of life. To evaluate the safety and tolerance of the subjects to Plasmodium immunotherapy, as well as the changes of tumor related indicators and immunological indicators.

Conditions

  • Advanced Ovarian Cancer

Interventions

BIOLOGICAL

Plasmodium immunotherapy

Inoculation 1-5 × 10\^6 Plasmodium vivax once

Sponsors & Collaborators

  • The Third Affiliated Hospital of Southern Medical University

    collaborator OTHER_GOV

  • CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Guo Shuiqun, Ph.D., M.D. · The Third Affiliated Hospital of Southern Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-20
Primary Completion
2026-11-30
Completion
2029-03-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05924776 on ClinicalTrials.gov